

***Candida albicans* dimorphism as a therapeutic target.**

Jacobsen ID, Wilson D, Wächtler B, Brunke S, Naglik JR, Hube B (2012) *Candida albicans* dimorphism as a therapeutic target. *Expert Rev Anti Infect Ther* 10(1), 85-93. (Review)

[Details](#)



Abstract

The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus *Candida albicans*. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of *C. albicans* dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.

Involved units

[Microbial Pathogenicity Mechanisms Bernhard Hube](#) [Read more](#)

[Microbial Immunology Ilse Jacobsen](#) [Read more](#)

Leibniz-HKI-Authors



Sascha Brunke

[Details](#)



Betty Hebecker

[Details](#)



Bernhard Hube

[Details](#)



Ilse Denise Jacobsen

[Details](#)



Duncan Wilson

[Details](#)

Identifier

doi: 10.1586/eri.11.152

PMID: 22149617